Experimental drug aims to tame dangerous hormone in dialysis patients
NCT ID NCT06747247
Summary
This study tested a drug called MT1013 for people on kidney dialysis who develop a bone-weakening condition called secondary hyperparathyroidism. Researchers gave 98 dialysis patients different doses of the drug or a placebo to check safety and see if it could lower a harmful hormone by at least 30%. The goal was to control this common dialysis complication and potentially improve bone health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.